Clearside Biomedical/CLSD

$1.36

6.75%
-
1D1W1MYTD1YMAX

About Clearside Biomedical

Clearside Biomedical, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering therapies to the back of the eye diseases through the suprachoroidal space (SCS). Its SCS injection platform utilizing its SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted delivery of a variety of therapies to the macula, retina or choroid to preserve and improve vision in patients with sight-threatening eye diseases. It is focused on developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector, and it also partners with companies developing other ophthalmic therapeutics to be administered using its SCS injection platform. Its lead product candidate, XIPERE, is a preservative-free suspension of the corticosteroid triamcinolone acetonide (TA), formulated for administration through suprachoroidal injection. Its pipeline includes CLS-AX, CLS-301 and Gene Therapy.
Ticker
CLSD
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology & Drugs
CEO
George Lasezkay
Employees
36
Headquarters
Alpharetta, United States

CLSD Metrics

BasicAdvanced
$101.62M
Market cap
-
P/E ratio
-$0.61
EPS
2.28
Beta
-
Dividend rate

What the Analysts think about CLSD

Analyst Ratings

Majority rating from 6 analysts.
Buy

Price Targets

Average projection from 6 analysts.
316.91% upside
High $8.00
Low $4.00
$1.36
Current price
$5.67
Average price target

CLSD Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-1,150% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$800K
-20%
Net income
$-9.2M
1.1%
Profit margin
-1,150%
26.37%

CLSD Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 3.23%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.16
-$0.15
-$0.15
-$0.15
-
Expected
-$0.13
-$0.14
-$0.14
-$0.16
-$0.09
Surprise
26.98%
7.14%
5.88%
-3.23%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Clearside Biomedical stock

Buy or sell Clearside Biomedical stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing